ResMed (RMD) to Release Earnings on Thursday

ResMed (NYSE:RMD) is expected to be posting its Q2 2026 results after the market closes on Thursday, January 29th. Analysts expect the company to announce earnings of $2.68 per share and revenue of $1.3967 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, January 29, 2026 at 4:30 PM ET.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The business had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the business posted $2.20 EPS. ResMed’s quarterly revenue was up 9.1% on a year-over-year basis. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Stock Up 2.4%

ResMed stock opened at $259.29 on Thursday. The firm has a market capitalization of $37.84 billion, a price-to-earnings ratio of 26.54, a price-to-earnings-growth ratio of 1.70 and a beta of 0.88. The firm’s fifty day moving average price is $249.74 and its two-hundred day moving average price is $263.26. ResMed has a 1-year low of $199.92 and a 1-year high of $293.81. The company has a current ratio of 2.89, a quick ratio of 2.13 and a debt-to-equity ratio of 0.07.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Thursday, November 13th were paid a $0.60 dividend. The ex-dividend date of this dividend was Thursday, November 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. ResMed’s dividend payout ratio is 24.56%.

Insider Activity

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total transaction of $497,660.00. Following the completion of the transaction, the director directly owned 66,773 shares of the company’s stock, valued at approximately $16,615,125.59. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,011 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $249.75, for a total value of $2,000,747.25. Following the completion of the sale, the chief executive officer directly owned 467,866 shares of the company’s stock, valued at $116,849,533.50. This represents a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 21,594 shares of company stock valued at $5,403,495 in the last three months. Company insiders own 0.65% of the company’s stock.

Institutional Trading of ResMed

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp boosted its stake in ResMed by 52.6% in the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock worth $645,000 after purchasing an additional 994 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ResMed in the second quarter worth about $389,000. Brown Advisory Inc. boosted its position in shares of ResMed by 17.8% in the second quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock valued at $409,000 after acquiring an additional 240 shares during the period. Cresset Asset Management LLC purchased a new position in ResMed during the second quarter valued at approximately $206,000. Finally, Alliancebernstein L.P. grew its stake in ResMed by 24.2% during the second quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock valued at $73,808,000 after acquiring an additional 55,790 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RMD. Morgan Stanley set a $305.00 target price on ResMed in a research report on Friday, October 31st. Stifel Nicolaus cut their price objective on shares of ResMed from $270.00 to $260.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Mizuho lowered their target price on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Robert W. Baird reissued a “neutral” rating and set a $275.00 price target (down from $300.00) on shares of ResMed in a research report on Tuesday, December 16th. Finally, Wells Fargo & Company started coverage on shares of ResMed in a research report on Monday, October 13th. They issued an “equal weight” rating and a $280.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $296.09.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.